KKL 顾客使用本产品发表的 0 篇科研文献

Cannabigerol, one of the major phytocannabinoids, behaves as a weak partial agonist at CB1 and CB2 receptors. Cannabigerol is also a relatively potent and highly effective TRPA1 agonist (EC₅₀=0.7μM), a weak agonist at TRPV1 and TRPV2 (1.3 and 1.72 μM, respectively), and a potent TRPM8 (0.16 μM) and 5-HT_1A receptor antagonist. Cannabigerol is a potent α2-adrenoceptor agonist (0.2 nM). Cannabigerol promotes apoptosis, stimulates reactive oxygen species (ROS) production, upregulates CHOP mRNA and reduces cell growth in CRC cells.

Cannabigerol (CBG) antagonizes the 5-HT_1A receptor agonist, R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin (apparent K_B=51.9 nM).
In CHO cells stably expressing human receptors, Cannabigerol is a weak partial agonist of both CB1R- and CB2R-dependent inhibition of cAMP that displaying a low affinity for CB1R and comparatively higher affinity for CB2R (K_i= 1300 and 490 nM, respectively). Cannabigerol (1-30 μM; 3-48 hurs) reduces cell viability in human colorectal cancer (Caco-2) cells in a time- and serum protein concentration-dependent manner.
Cannabigerol (10 μM; 24 hours) induces apoptosis in colorectal cancer (Caco-2) cells.

Cannabigerol (1-10 mg/kg; intraperitoneally; every day for 5 days; athymic female mice bearing HCT 116 cells) reduces colon carcinogenesis in vivo.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.